Skip to main content
Erschienen in: Advances in Therapy 4/2019

12.03.2019 | Guidelines

Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing

verfasst von: Kumar Prabhash, Suresh H. Advani, Ullas Batra, Bivas Biswas, Anuradha Chougule, Mithua Ghosh, Vamshi Krishna Muddu, T. P. Sahoo, Ashok K. Vaid

Erschienen in: Advances in Therapy | Ausgabe 4/2019

Einloggen, um Zugang zu erhalten

Abstract

Novel molecular targets and promising targeted therapies have reshaped diagnostics in patients with advanced non-small cell lung cancer (NSCLC). Despite this progress, the implementation of molecular screening to identify predictive biomarkers in Indian clinical and pathology settings has been challenging due to operational and logistical constraints. This consensus guideline brings together medical oncologists, molecular pathologists and pathologists from India to provide a quick and competent reference for biomarker testing in NSCLC. The guideline summarizes the importance of targetable mutations in NSCLC such as epidermal growth factor receptor (EGFR), rearrangements in anaplastic lymphoma kinase and receptor tyrosine kinase encoded by ROS-1 gene, overexpression of programmed cell death ligand-1 and resistant EGFR mutations. It reaffirms recommendations from international working groups, discusses vulnerable pre-analytical procedures and provides a balanced review on the pros and cons of different diagnostic tests (immunohistochemistry, fluorescence in situ hybridization, polymerase chain reaction-based testing and next-generation sequencing). The document also provides an algorithm to aid diagnostic decision-making and a checklist to assess the quality of testing laboratories that will help the medical oncologists make an informed choice. Overall, these recommendations are based on evidence and clinical experience and will aid policymakers, oncologists, health care practitioners and pathologists who strive to implement molecular strategies and make informed decisions for improved care in NSCLC in India.
Funding: AstraZeneca Pharma India Limited.
Literatur
1.
2.
Zurück zum Zitat Desai C, Mehta A, Mishra D. Usage patterns of biomarkers in non-small-cell lung cancer patients in India: findings from a systematic review and survey. Lung India. 2014;31(3):249–59.CrossRefPubMedPubMedCentral Desai C, Mehta A, Mishra D. Usage patterns of biomarkers in non-small-cell lung cancer patients in India: findings from a systematic review and survey. Lung India. 2014;31(3):249–59.CrossRefPubMedPubMedCentral
5.
Zurück zum Zitat Nair C, Mathew A, George P. Lung cancer: presentation and pattern of care in a cancer center in South India. Indian J Cancer. 2017;54(1):164–8.CrossRefPubMed Nair C, Mathew A, George P. Lung cancer: presentation and pattern of care in a cancer center in South India. Indian J Cancer. 2017;54(1):164–8.CrossRefPubMed
6.
Zurück zum Zitat Shankar S, Thanasekaran V, Dhanasekar T, Duvooru P. Clinicopathological and immunohistochemical profile of non-small cell lung carcinoma in a tertiary care medical centre in South India. Lung India. 2014;31(1):23–8.CrossRefPubMedPubMedCentral Shankar S, Thanasekaran V, Dhanasekar T, Duvooru P. Clinicopathological and immunohistochemical profile of non-small cell lung carcinoma in a tertiary care medical centre in South India. Lung India. 2014;31(1):23–8.CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Mohan A, Latifi AN, Guleria R. Increasing incidence of adenocarcinoma lung in India: following the global trend? Indian J Cancer. 2016;53(1):92–5.CrossRefPubMed Mohan A, Latifi AN, Guleria R. Increasing incidence of adenocarcinoma lung in India: following the global trend? Indian J Cancer. 2016;53(1):92–5.CrossRefPubMed
8.
Zurück zum Zitat Azzoli CG, Temin S, Giaccone G. 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Oncol Pract. 2012;8(1):63–6.CrossRefPubMed Azzoli CG, Temin S, Giaccone G. 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Oncol Pract. 2012;8(1):63–6.CrossRefPubMed
9.
Zurück zum Zitat Ho C, Tong KM, Ramsden K, Ionescu DN, Laskin J. Histologic classification of non-small-cell lung cancer over time: reducing the rates of not-otherwise-specified. Curr Oncol. 2015;22(3):e164–70.CrossRefPubMedPubMedCentral Ho C, Tong KM, Ramsden K, Ionescu DN, Laskin J. Histologic classification of non-small-cell lung cancer over time: reducing the rates of not-otherwise-specified. Curr Oncol. 2015;22(3):e164–70.CrossRefPubMedPubMedCentral
10.
Zurück zum Zitat Azzoli CG, Temin S, Aliff T, et al. 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2011;29(28):3825–31.CrossRefPubMedPubMedCentral Azzoli CG, Temin S, Aliff T, et al. 2011 focused update of 2009 American Society of Clinical Oncology Clinical Practice Guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol. 2011;29(28):3825–31.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99(11):847–57.CrossRefPubMed Ardizzoni A, Boni L, Tiseo M, et al. Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis. J Natl Cancer Inst. 2007;99(11):847–57.CrossRefPubMed
12.
Zurück zum Zitat D’Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005;23(13):2926–36.CrossRefPubMed D’Addario G, Pintilie M, Leighl NB, Feld R, Cerny T, Shepherd FA. Platinum-based versus non-platinum-based chemotherapy in advanced non-small-cell lung cancer: a meta-analysis of the published literature. J Clin Oncol. 2005;23(13):2926–36.CrossRefPubMed
13.
Zurück zum Zitat Valdes M, Nicholas G, Goss GD, Wheatley-Price P. Chemotherapy in recurrent advanced non-small-cell lung cancer after adjuvant chemotherapy. Curr Oncol. 2016;23(6):386–90.CrossRefPubMedPubMedCentral Valdes M, Nicholas G, Goss GD, Wheatley-Price P. Chemotherapy in recurrent advanced non-small-cell lung cancer after adjuvant chemotherapy. Curr Oncol. 2016;23(6):386–90.CrossRefPubMedPubMedCentral
14.
Zurück zum Zitat Forde PM, Ettinger DS. Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther. 2013;13(6):745–58.CrossRefPubMedPubMedCentral Forde PM, Ettinger DS. Targeted therapy for non-small-cell lung cancer: past, present and future. Expert Rev Anticancer Ther. 2013;13(6):745–58.CrossRefPubMedPubMedCentral
15.
Zurück zum Zitat Sirohi B, Ashley S, Norton A, et al. Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival. J Thoracic Oncol. 2007;2(8):735–40.CrossRef Sirohi B, Ashley S, Norton A, et al. Early response to platinum-based first-line chemotherapy in non-small cell lung cancer may predict survival. J Thoracic Oncol. 2007;2(8):735–40.CrossRef
16.
Zurück zum Zitat Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535–46.CrossRefPubMedPubMedCentral Chen Z, Fillmore CM, Hammerman PS, Kim CF, Wong KK. Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014;14(8):535–46.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Sholl LM, Aisner DL, Varella-Garcia M, et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the Lung Cancer Mutation Consortium experience. J Thoracic Oncol. 2015;10(5):768–77.CrossRef Sholl LM, Aisner DL, Varella-Garcia M, et al. Multi-institutional oncogenic driver mutation analysis in lung adenocarcinoma: the Lung Cancer Mutation Consortium experience. J Thoracic Oncol. 2015;10(5):768–77.CrossRef
19.
Zurück zum Zitat Korpanty GJ, Graham DM, Vincent MD, Leighl NB. Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front Oncol. 2014;4:204.CrossRefPubMedPubMedCentral Korpanty GJ, Graham DM, Vincent MD, Leighl NB. Biomarkers that currently affect clinical practice in lung cancer: EGFR, ALK, MET, ROS-1, and KRAS. Front Oncol. 2014;4:204.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Stanek L, Springer D, Konopasek B, et al. Molecular pathological predictive diagnostics in a patient with non-small cell lung cancer treated with crizotinib therapy: a case report. Oncol Lett. 2017;14(6):7545–8.PubMedPubMedCentral Stanek L, Springer D, Konopasek B, et al. Molecular pathological predictive diagnostics in a patient with non-small cell lung cancer treated with crizotinib therapy: a case report. Oncol Lett. 2017;14(6):7545–8.PubMedPubMedCentral
21.
Zurück zum Zitat Saito S, Espinoza-Mercado F, Liu H, Sata N, Cui X, Soukiasian HJ. Current status of research and treatment for non-small cell lung cancer in never-smoking females. Cancer Biol Ther. 2017;18(6):359–68.CrossRefPubMedPubMedCentral Saito S, Espinoza-Mercado F, Liu H, Sata N, Cui X, Soukiasian HJ. Current status of research and treatment for non-small cell lung cancer in never-smoking females. Cancer Biol Ther. 2017;18(6):359–68.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311.CrossRefPubMed Hirsch FR, Scagliotti GV, Mulshine JL, et al. Lung cancer: current therapies and new targeted treatments. Lancet. 2017;389(10066):299–311.CrossRefPubMed
23.
Zurück zum Zitat Tsao AS, Scagliotti GV, Bunn PA Jr, et al. Scientific advances in lung cancer 2015. J Thoracic Oncol. 2016;11(5):613–38.CrossRef Tsao AS, Scagliotti GV, Bunn PA Jr, et al. Scientific advances in lung cancer 2015. J Thoracic Oncol. 2016;11(5):613–38.CrossRef
24.
Zurück zum Zitat Jett JR, Carr LL. Targeted therapy for non-small cell lung cancer. Am J Respir Crit Care Med. 2013;188(8):907–12.CrossRefPubMed Jett JR, Carr LL. Targeted therapy for non-small cell lung cancer. Am J Respir Crit Care Med. 2013;188(8):907–12.CrossRefPubMed
25.
Zurück zum Zitat Spigel DR, Schrock AB, Fabrizio D, et al. Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies. J Clin Oncol. 2016;34(15_suppl):9017.CrossRef Spigel DR, Schrock AB, Fabrizio D, et al. Total mutation burden (TMB) in lung cancer (LC) and relationship with response to PD-1/PD-L1 targeted therapies. J Clin Oncol. 2016;34(15_suppl):9017.CrossRef
26.
27.
Zurück zum Zitat Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28.CrossRefPubMed Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med. 2015;372(21):2018–28.CrossRefPubMed
28.
Zurück zum Zitat Chandra S, Mohan A, Guleria R, Singh V, Yadav P. Delays during the diagnostic evaluation and treatment of lung cancer. Asian Pac J Cancer Prev. 2009;10(3):453–6.PubMed Chandra S, Mohan A, Guleria R, Singh V, Yadav P. Delays during the diagnostic evaluation and treatment of lung cancer. Asian Pac J Cancer Prev. 2009;10(3):453–6.PubMed
29.
Zurück zum Zitat Singh VK, Chandra S, Kumar S, Pangtey G, Mohan A, Guleria R. A common medical error: lung cancer misdiagnosed as sputum negative tuberculosis. Asian Pac J Cancer Prev. 2009;10(3):335–8.PubMed Singh VK, Chandra S, Kumar S, Pangtey G, Mohan A, Guleria R. A common medical error: lung cancer misdiagnosed as sputum negative tuberculosis. Asian Pac J Cancer Prev. 2009;10(3):335–8.PubMed
30.
Zurück zum Zitat Bjerager M, Palshof T, Dahl R, Vedsted P, Olesen F. Delay in diagnosis of lung cancer in general practice. Br J Gen Pract. 2006;56(532):863–8.PubMedPubMedCentral Bjerager M, Palshof T, Dahl R, Vedsted P, Olesen F. Delay in diagnosis of lung cancer in general practice. Br J Gen Pract. 2006;56(532):863–8.PubMedPubMedCentral
31.
Zurück zum Zitat Lim C, Tsao MS, Le LW, et al. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. Ann Oncol. 2015;26(7):1415–21.CrossRefPubMed Lim C, Tsao MS, Le LW, et al. Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. Ann Oncol. 2015;26(7):1415–21.CrossRefPubMed
32.
Zurück zum Zitat Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–81.CrossRefPubMed Sharma SV, Bell DW, Settleman J, Haber DA. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169–81.CrossRefPubMed
33.
Zurück zum Zitat Chougule A, Prabhash K, Noronha V, et al. Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity. PLoS ONE. 2013;8(10):e76164.CrossRefPubMedPubMedCentral Chougule A, Prabhash K, Noronha V, et al. Frequency of EGFR mutations in 907 lung adenocarcioma patients of Indian ethnicity. PLoS ONE. 2013;8(10):e76164.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Doval D, Prabhash K, Patil S, et al. Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung. OncoTargets Therapy. 2015;8:117–23.PubMedPubMedCentral Doval D, Prabhash K, Patil S, et al. Clinical and epidemiological study of EGFR mutations and EML4-ALK fusion genes among Indian patients with adenocarcinoma of the lung. OncoTargets Therapy. 2015;8:117–23.PubMedPubMedCentral
35.
Zurück zum Zitat Aggarwal S, Patil S, Minhans S, Pungliya M, Soumitra N. A study of EGFR mutation in nonsmoker NSCLC: Striking disparity between north and south India patients. J Clin Oncol. 2012;30(15):e18041–e18041. Aggarwal S, Patil S, Minhans S, Pungliya M, Soumitra N. A study of EGFR mutation in nonsmoker NSCLC: Striking disparity between north and south India patients. J Clin Oncol. 2012;30(15):e18041–e18041.
36.
Zurück zum Zitat Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thoracic Oncol. 2014;9(2):154–62.CrossRef Shi Y, Au JS, Thongprasert S, et al. A prospective, molecular epidemiology study of EGFR mutations in Asian patients with advanced non-small-cell lung cancer of adenocarcinoma histology (PIONEER). J Thoracic Oncol. 2014;9(2):154–62.CrossRef
37.
Zurück zum Zitat Joshi A, Zanwar S, Noronha V, et al. EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas? OncoTargets Therapy. 2017;10:1859–63.CrossRefPubMedPubMedCentral Joshi A, Zanwar S, Noronha V, et al. EGFR mutation in squamous cell carcinoma of the lung: does it carry the same connotation as in adenocarcinomas? OncoTargets Therapy. 2017;10:1859–63.CrossRefPubMedPubMedCentral
38.
Zurück zum Zitat Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2013;66(2):79–89.CrossRefPubMed Ellison G, Zhu G, Moulis A, Dearden S, Speake G, McCormack R. EGFR mutation testing in lung cancer: a review of available methods and their use for analysis of tumour tissue and cytology samples. J Clin Pathol. 2013;66(2):79–89.CrossRefPubMed
39.
Zurück zum Zitat Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharmaceut Sinica B. 2015;5(5):390–401.CrossRef Huang L, Fu L. Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharmaceut Sinica B. 2015;5(5):390–401.CrossRef
40.
Zurück zum Zitat Singh N, Vishwanath G, Aggarwal AN, Behera D. Clinical experience on use of oral EGFR-TKIs as first-line treatment of advanced NSCLC from a tertiary care centre in North India and implications of skin rash. Indian J Chest Dis Allied Sci. 2014;56(3):149–52.PubMed Singh N, Vishwanath G, Aggarwal AN, Behera D. Clinical experience on use of oral EGFR-TKIs as first-line treatment of advanced NSCLC from a tertiary care centre in North India and implications of skin rash. Indian J Chest Dis Allied Sci. 2014;56(3):149–52.PubMed
41.
Zurück zum Zitat Singh N, Jindal A, Behera D. Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: a clinical perspective and review of published literature. World J Clin Oncol. 2014;5(5):858–64.CrossRefPubMedPubMedCentral Singh N, Jindal A, Behera D. Erlotinib usage after prior treatment with gefitinib in advanced non-small cell lung cancer: a clinical perspective and review of published literature. World J Clin Oncol. 2014;5(5):858–64.CrossRefPubMedPubMedCentral
42.
Zurück zum Zitat Bhatt AD, Pai R, Rebekah G, et al. Clinicopathologic features of non-small cell lung cancer in India and correlation with epidermal growth factor receptor mutational status. Indian J Cancer. 2013;50(2):94–101.CrossRefPubMed Bhatt AD, Pai R, Rebekah G, et al. Clinicopathologic features of non-small cell lung cancer in India and correlation with epidermal growth factor receptor mutational status. Indian J Cancer. 2013;50(2):94–101.CrossRefPubMed
43.
Zurück zum Zitat Noronha V, Prabhash K, Thavamani A, et al. EGFR mutations in Indian lung cancer patients: clinical correlation and outcome to EGFR targeted therapy. PLoS ONE. 2013;8(4):e61561.CrossRefPubMedPubMedCentral Noronha V, Prabhash K, Thavamani A, et al. EGFR mutations in Indian lung cancer patients: clinical correlation and outcome to EGFR targeted therapy. PLoS ONE. 2013;8(4):e61561.CrossRefPubMedPubMedCentral
44.
Zurück zum Zitat Desai SS, Shah AS, Prabhash K, Jambhekar NA. A year of anaplastic large cell kinase testing for lung carcinoma: pathological and technical perspectives. Indian J Cancer. 2013;50(2):80–6.CrossRefPubMed Desai SS, Shah AS, Prabhash K, Jambhekar NA. A year of anaplastic large cell kinase testing for lung carcinoma: pathological and technical perspectives. Indian J Cancer. 2013;50(2):80–6.CrossRefPubMed
45.
Zurück zum Zitat Kim HR, Lim SM, Kim HJ, et al. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol. 2013;24(9):2364–70.CrossRefPubMed Kim HR, Lim SM, Kim HJ, et al. The frequency and impact of ROS1 rearrangement on clinical outcomes in never smokers with lung adenocarcinoma. Ann Oncol. 2013;24(9):2364–70.CrossRefPubMed
46.
Zurück zum Zitat Casaluce F, Sgambato A, Maione P, et al. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Targeted Oncol. 2013;8(1):55–67.CrossRef Casaluce F, Sgambato A, Maione P, et al. ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC. Targeted Oncol. 2013;8(1):55–67.CrossRef
47.
Zurück zum Zitat Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer (Oxford, England: 1990). 2010;46(10):1773–80.CrossRef Sasaki T, Rodig SJ, Chirieac LR, Janne PA. The biology and treatment of EML4-ALK non-small cell lung cancer. Eur J Cancer (Oxford, England: 1990). 2010;46(10):1773–80.CrossRef
48.
Zurück zum Zitat Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190–203.CrossRefPubMed Rikova K, Guo A, Zeng Q, et al. Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer. Cell. 2007;131(6):1190–203.CrossRefPubMed
49.
Zurück zum Zitat Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142(3):321–46.CrossRefPubMed Lindeman NI, Cagle PT, Aisner DL, et al. Updated molecular testing guideline for the selection of lung cancer patients for treatment with targeted tyrosine kinase inhibitors: guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. Arch Pathol Lab Med. 2018;142(3):321–46.CrossRefPubMed
50.
Zurück zum Zitat Noronha V, Chandrakanth MV, Joshi AP, et al. ROS1 rearranged nonsmall cell lung cancer and crizotinib: an Indian experience. Indian J Cancer. 2017;54(2):436–8.CrossRefPubMed Noronha V, Chandrakanth MV, Joshi AP, et al. ROS1 rearranged nonsmall cell lung cancer and crizotinib: an Indian experience. Indian J Cancer. 2017;54(2):436–8.CrossRefPubMed
51.
Zurück zum Zitat Noronha V, Ramaswamy A, Patil VM, et al. ALK positive lung cancer: clinical profile, practice and outcomes in a developing country. PLoS ONE. 2016;11(9):e0160752.CrossRefPubMedPubMedCentral Noronha V, Ramaswamy A, Patil VM, et al. ALK positive lung cancer: clinical profile, practice and outcomes in a developing country. PLoS ONE. 2016;11(9):e0160752.CrossRefPubMedPubMedCentral
52.
Zurück zum Zitat Abdallah SM, Wong A. Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options? Curr Oncol. 2018;25(Suppl 1):S103–14.CrossRefPubMedPubMedCentral Abdallah SM, Wong A. Brain metastases in non-small-cell lung cancer: are tyrosine kinase inhibitors and checkpoint inhibitors now viable options? Curr Oncol. 2018;25(Suppl 1):S103–14.CrossRefPubMedPubMedCentral
53.
Zurück zum Zitat Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.CrossRefPubMedPubMedCentral Alsaab HO, Sau S, Alzhrani R, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.CrossRefPubMedPubMedCentral
55.
Zurück zum Zitat Zhang M, Li G, Wang Y, et al. PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. Sci Rep. 2017;7(1):10255.CrossRefPubMedPubMedCentral Zhang M, Li G, Wang Y, et al. PD-L1 expression in lung cancer and its correlation with driver mutations: a meta-analysis. Sci Rep. 2017;7(1):10255.CrossRefPubMedPubMedCentral
56.
Zurück zum Zitat Aguiar PN Jr, De Mello RA, Hall P, Tadokoro H, Lima Lopes G. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. Immunotherapy. 2017;9(6):499–506.CrossRefPubMed Aguiar PN Jr, De Mello RA, Hall P, Tadokoro H, Lima Lopes G. PD-L1 expression as a predictive biomarker in advanced non-small-cell lung cancer: updated survival data. Immunotherapy. 2017;9(6):499–506.CrossRefPubMed
57.
Zurück zum Zitat Vallonthaiel AG, Malik PS, Singh V, et al. Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: a report from India. Ann Diagn Pathol. 2017;31:56–61.CrossRefPubMed Vallonthaiel AG, Malik PS, Singh V, et al. Clinicopathologic correlation of programmed death ligand-1 expression in non-small cell lung carcinomas: a report from India. Ann Diagn Pathol. 2017;31:56–61.CrossRefPubMed
58.
Zurück zum Zitat Veldore VH, Patil S, Satheesh CT, et al. Genomic profiling in a homogeneous molecular subtype of non-small cell lung cancer: an effort to explore new drug targets. Indian J Cancer. 2015;52(2):243–8.CrossRefPubMed Veldore VH, Patil S, Satheesh CT, et al. Genomic profiling in a homogeneous molecular subtype of non-small cell lung cancer: an effort to explore new drug targets. Indian J Cancer. 2015;52(2):243–8.CrossRefPubMed
59.
Zurück zum Zitat Jacob LA, Lakshmaiah K, Govindbabu K, et al. Genomic profiling of non-small cell lung cancer: a pilot study from South India. Int J Mol Immuno Oncol. 2017;2(2):63–6.CrossRef Jacob LA, Lakshmaiah K, Govindbabu K, et al. Genomic profiling of non-small cell lung cancer: a pilot study from South India. Int J Mol Immuno Oncol. 2017;2(2):63–6.CrossRef
60.
Zurück zum Zitat Thungappa S, Patil S, Shashidhara H, et al. P2. 03b-064 genomic profiling in non-small cell lung cancer: new hope for personalized medicine: topic: biomarkers. J Thoracic Oncol. 2017;12(1):974–5.CrossRef Thungappa S, Patil S, Shashidhara H, et al. P2. 03b-064 genomic profiling in non-small cell lung cancer: new hope for personalized medicine: topic: biomarkers. J Thoracic Oncol. 2017;12(1):974–5.CrossRef
61.
Zurück zum Zitat Pathak A, Rajappa S, Gore A. Oncogenic drivers in nonsmall cell lung cancer and resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Indian J Cancer. 2017;54(Supplement):S1–8.CrossRefPubMed Pathak A, Rajappa S, Gore A. Oncogenic drivers in nonsmall cell lung cancer and resistance to epidermal growth factor receptor tyrosine kinase inhibitors. Indian J Cancer. 2017;54(Supplement):S1–8.CrossRefPubMed
62.
Zurück zum Zitat Weart TC, Miller KD, Simone CB 2nd. Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy. Cancer Manag Res. 2018;10:647–52.CrossRefPubMedPubMedCentral Weart TC, Miller KD, Simone CB 2nd. Spotlight on dabrafenib/trametinib in the treatment of non-small-cell lung cancer: place in therapy. Cancer Manag Res. 2018;10:647–52.CrossRefPubMedPubMedCentral
63.
Zurück zum Zitat Planchard D, Besse B, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17(7):984–93.CrossRefPubMedPubMedCentral Planchard D, Besse B, Groen HJM, et al. Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial. Lancet Oncol. 2016;17(7):984–93.CrossRefPubMedPubMedCentral
64.
Zurück zum Zitat Kerr KM, Bubendorf L, Edelman MJ, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol. 2014;25(9):1681–90.CrossRefPubMed Kerr KM, Bubendorf L, Edelman MJ, et al. Second ESMO consensus conference on lung cancer: pathology and molecular biomarkers for non-small-cell lung cancer. Ann Oncol. 2014;25(9):1681–90.CrossRefPubMed
65.
Zurück zum Zitat Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thoracic Oncol. 2013;8(7):823–59.CrossRef Lindeman NI, Cagle PT, Beasley MB, et al. Molecular testing guideline for selection of lung cancer patients for EGFR and ALK tyrosine kinase inhibitors: guideline from the College of American Pathologists, International Association for the Study of Lung Cancer, and Association for Molecular Pathology. J Thoracic Oncol. 2013;8(7):823–59.CrossRef
66.
Zurück zum Zitat Garrido P, de Castro J, Concha A, et al. Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clin Trans Oncol. 2012;14(5):338–349. Garrido P, de Castro J, Concha A, et al. Guidelines for biomarker testing in advanced non-small-cell lung cancer. A national consensus of the Spanish Society of Medical Oncology (SEOM) and the Spanish Society of Pathology (SEAP). Clin Trans Oncol. 2012;14(5):338–349.
67.
Zurück zum Zitat Iding JS, Krimsky W, Browning R. Tissue requirements in lung cancer diagnosis for tumor heterogeneity, mutational analysis and targeted therapies: initial experience with intra-operative Frozen Section Evaluation (FROSE) in bronchoscopic biopsies. J Thoracic Dis. 2016;8(Suppl 6):S488–93.CrossRef Iding JS, Krimsky W, Browning R. Tissue requirements in lung cancer diagnosis for tumor heterogeneity, mutational analysis and targeted therapies: initial experience with intra-operative Frozen Section Evaluation (FROSE) in bronchoscopic biopsies. J Thoracic Dis. 2016;8(Suppl 6):S488–93.CrossRef
68.
Zurück zum Zitat Hu YC, Zhang Q, Huang YH, Liu YF, Chen HL. Comparison of two methods to extract DNA from formalin-fixed, paraffin-embedded tissues and their impact on EGFR mutation detection in non-small cell lung carcinoma. Asian Pac J Cancer Prev. 2014;15(6):2733–7.CrossRefPubMed Hu YC, Zhang Q, Huang YH, Liu YF, Chen HL. Comparison of two methods to extract DNA from formalin-fixed, paraffin-embedded tissues and their impact on EGFR mutation detection in non-small cell lung carcinoma. Asian Pac J Cancer Prev. 2014;15(6):2733–7.CrossRefPubMed
69.
Zurück zum Zitat Muley TR, Herth FJ, Schnabel PA, Dienemann H, Meister M. From tissue to molecular phenotyping: pre-analytical requirements heidelberg experience. Transl Lung Cancer Res. 2012;1(2):111–21.PubMedPubMedCentral Muley TR, Herth FJ, Schnabel PA, Dienemann H, Meister M. From tissue to molecular phenotyping: pre-analytical requirements heidelberg experience. Transl Lung Cancer Res. 2012;1(2):111–21.PubMedPubMedCentral
70.
Zurück zum Zitat Dietel M, Bubendorf L, Dingemans AM, et al. Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. Thorax. 2016;71(2):177–84.CrossRefPubMed Dietel M, Bubendorf L, Dingemans AM, et al. Diagnostic procedures for non-small-cell lung cancer (NSCLC): recommendations of the European Expert Group. Thorax. 2016;71(2):177–84.CrossRefPubMed
71.
Zurück zum Zitat Raja T, Warrier N. Epidermal growth factor receptor mutation testing: from conventional to real-time diagnosis of lung cancer. Indian J Cancer. 2017;54(5):9–14.CrossRef Raja T, Warrier N. Epidermal growth factor receptor mutation testing: from conventional to real-time diagnosis of lung cancer. Indian J Cancer. 2017;54(5):9–14.CrossRef
72.
Zurück zum Zitat Warth A, Penzel R, Brandt R, et al. Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies. Virchows Arch. 2012;460(4):407–14.CrossRefPubMed Warth A, Penzel R, Brandt R, et al. Optimized algorithm for Sanger sequencing-based EGFR mutation analyses in NSCLC biopsies. Virchows Arch. 2012;460(4):407–14.CrossRefPubMed
73.
Zurück zum Zitat O’Donnell P, Ferguson J, Shyu J, et al. Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. BMC Cancer. 2013;13:210.CrossRefPubMedPubMedCentral O’Donnell P, Ferguson J, Shyu J, et al. Analytic performance studies and clinical reproducibility of a real-time PCR assay for the detection of epidermal growth factor receptor gene mutations in formalin-fixed paraffin-embedded tissue specimens of non-small cell lung cancer. BMC Cancer. 2013;13:210.CrossRefPubMedPubMedCentral
74.
Zurück zum Zitat Prabhash K, Parikh PM, Noronha V, et al. Patterns of EGFR testing for lung cancer among tertiary care centers in India. J Clin Oncol. 2015;33(15_suppl):e19114–e19114. Prabhash K, Parikh PM, Noronha V, et al. Patterns of EGFR testing for lung cancer among tertiary care centers in India. J Clin Oncol. 2015;33(15_suppl):e19114–e19114.
75.
Zurück zum Zitat Raja T, Warrier NK. Epidermal growth factor receptor mutation testing: from conventional to real-time diagnosis of lung cancer. Indian J Cancer. 2017;54(Supplement):S9–14.CrossRefPubMed Raja T, Warrier NK. Epidermal growth factor receptor mutation testing: from conventional to real-time diagnosis of lung cancer. Indian J Cancer. 2017;54(Supplement):S9–14.CrossRefPubMed
76.
Zurück zum Zitat Patil VM, Noronha V, Joshi A, et al. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open. 2017;2(1):e000168.CrossRefPubMedPubMedCentral Patil VM, Noronha V, Joshi A, et al. Phase III study of gefitinib or pemetrexed with carboplatin in EGFR-mutated advanced lung adenocarcinoma. ESMO Open. 2017;2(1):e000168.CrossRefPubMedPubMedCentral
77.
Zurück zum Zitat Sahoo R, Harini VV, Babu VC, et al. Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer (Amsterdam, Netherlands). 2011;73(3):316–9.CrossRef Sahoo R, Harini VV, Babu VC, et al. Screening for EGFR mutations in lung cancer, a report from India. Lung Cancer (Amsterdam, Netherlands). 2011;73(3):316–9.CrossRef
78.
Zurück zum Zitat Veldore V, Rao R, Kakara S, et al. Epidermal growth factor receptor mutation in non-small-cell lung carcinomas: a retrospective analysis of 1036 lung cancer specimens from a network of tertiary cancer care centers in India. Indian J Cancer. 2013;50(2):87–93.CrossRefPubMed Veldore V, Rao R, Kakara S, et al. Epidermal growth factor receptor mutation in non-small-cell lung carcinomas: a retrospective analysis of 1036 lung cancer specimens from a network of tertiary cancer care centers in India. Indian J Cancer. 2013;50(2):87–93.CrossRefPubMed
79.
Zurück zum Zitat Young EC, Owens MM, Adebiyi I, et al. A comparison of methods for EGFR mutation testing in non-small cell lung cancer. Diagn Mol Pathol. 2013;22(4):190–5.CrossRefPubMed Young EC, Owens MM, Adebiyi I, et al. A comparison of methods for EGFR mutation testing in non-small cell lung cancer. Diagn Mol Pathol. 2013;22(4):190–5.CrossRefPubMed
80.
Zurück zum Zitat Prabhash K, Parikh PM, Rajappa SJ, et al. EGFR testing scenario across 111 centres in India: a questionnaire-based survey. J Clin Oncol. 2017;35(15_suppl):e13111–e13111. Prabhash K, Parikh PM, Rajappa SJ, et al. EGFR testing scenario across 111 centres in India: a questionnaire-based survey. J Clin Oncol. 2017;35(15_suppl):e13111–e13111.
81.
Zurück zum Zitat Pauwels P, Remmelink M, Hoton D, et al. Pathological diagnosis and molecular testing in non-small cell lung cancer: belgian guidelines. Belg J Med Oncol. 2016;10(4):123–31. Pauwels P, Remmelink M, Hoton D, et al. Pathological diagnosis and molecular testing in non-small cell lung cancer: belgian guidelines. Belg J Med Oncol. 2016;10(4):123–31.
82.
Zurück zum Zitat Singh R, Rohtagi N. Clinicopathological and molecular epidemiological study of lung cancer patients seen at a tertiary care hospital in Northern India. S Asian J Cancer. 2017;6(4):171–5.CrossRef Singh R, Rohtagi N. Clinicopathological and molecular epidemiological study of lung cancer patients seen at a tertiary care hospital in Northern India. S Asian J Cancer. 2017;6(4):171–5.CrossRef
83.
Zurück zum Zitat Chatterjee K, Bhowmik R, Chattopadhyay B. Regional reporting of the incidence of Anaplastic Lymphoma Kinase mutation in 379 non-small-cell lung cancer patients from Kolkata: using immunohistochemistry as the diagnostic modality in a significant subset. S Asian J Cancer. 2017;6(4):169–70.CrossRef Chatterjee K, Bhowmik R, Chattopadhyay B. Regional reporting of the incidence of Anaplastic Lymphoma Kinase mutation in 379 non-small-cell lung cancer patients from Kolkata: using immunohistochemistry as the diagnostic modality in a significant subset. S Asian J Cancer. 2017;6(4):169–70.CrossRef
84.
Zurück zum Zitat Bal A, Singh N, Agarwal P, Das A, Behera D. ALK gene rearranged lung adenocarcinomas: molecular genetics and morphology in cohort of patients from North India. APMIS. 2016;124(10):832–8.CrossRefPubMed Bal A, Singh N, Agarwal P, Das A, Behera D. ALK gene rearranged lung adenocarcinomas: molecular genetics and morphology in cohort of patients from North India. APMIS. 2016;124(10):832–8.CrossRefPubMed
85.
Zurück zum Zitat Wagle PB, Jambhekar NA, Kumar R, et al. A comparative analysis of immunohistochemistry and fluorescent in situ hybridization assay to detect anaplastic lymphoma kinase status in lung adenocarcinoma cases: a search for a testing algorithm. Indian J Cancer. 2017;54(1):148–54.CrossRefPubMed Wagle PB, Jambhekar NA, Kumar R, et al. A comparative analysis of immunohistochemistry and fluorescent in situ hybridization assay to detect anaplastic lymphoma kinase status in lung adenocarcinoma cases: a search for a testing algorithm. Indian J Cancer. 2017;54(1):148–54.CrossRefPubMed
86.
Zurück zum Zitat Batra U, Aggarwal M, Jain P, et al. Clinical outcome study of crizotinib in immunohistochemistry-proven echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene among Indian patients with adenocarcinoma lung. South Asian J Cancer. 2018;7(1):61–4.PubMedPubMedCentral Batra U, Aggarwal M, Jain P, et al. Clinical outcome study of crizotinib in immunohistochemistry-proven echinoderm microtubule-associated protein-like 4-anaplastic lymphoma kinase fusion gene among Indian patients with adenocarcinoma lung. South Asian J Cancer. 2018;7(1):61–4.PubMedPubMedCentral
87.
Zurück zum Zitat Joshua JM, Salima K, Pavithran K, Vijayan M. Crizotinib, an effective agent in ROS1-rearranged adenocarcinoma of lungs: a case report.Clinical medicine insights. Case Rep. 2018;11:1179547617749615. Joshua JM, Salima K, Pavithran K, Vijayan M. Crizotinib, an effective agent in ROS1-rearranged adenocarcinoma of lungs: a case report.Clinical medicine insights. Case Rep. 2018;11:1179547617749615.
88.
Zurück zum Zitat Suryavanshi M, Panigrahi MK, Kumar D, et al. ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer. Lung India. 2017;34(5):411–4.PubMedPubMedCentral Suryavanshi M, Panigrahi MK, Kumar D, et al. ROS1 rearrangement and response to crizotinib in Stage IV non-small cell lung cancer. Lung India. 2017;34(5):411–4.PubMedPubMedCentral
89.
Zurück zum Zitat Udall M, Rizzo M, Kenny J, et al. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagn Pathol. 2018;13(1):12.CrossRefPubMedPubMedCentral Udall M, Rizzo M, Kenny J, et al. PD-L1 diagnostic tests: a systematic literature review of scoring algorithms and test-validation metrics. Diagn Pathol. 2018;13(1):12.CrossRefPubMedPubMedCentral
90.
Zurück zum Zitat Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.CrossRefPubMed Herbst RS, Baas P, Kim DW, et al. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2016;387(10027):1540–50.CrossRefPubMed
91.
Zurück zum Zitat Kosaka T, Yamaki E, Mogi A, Kuwano H. Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol. 2011;2011:165214CrossRefPubMedPubMedCentral Kosaka T, Yamaki E, Mogi A, Kuwano H. Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol. 2011;2011:165214CrossRefPubMedPubMedCentral
92.
Zurück zum Zitat Advani S, Malhotra H, Chacko R, et al. Advanced therapeutic options and importance of repeat biopsy in epidermal growth factor receptor-tyrosine kinase inhibitor-progressed nonsmall cell lung carcinoma patients: an expert opinion. Indian J Cancer. 2017;54(5):31–6.CrossRef Advani S, Malhotra H, Chacko R, et al. Advanced therapeutic options and importance of repeat biopsy in epidermal growth factor receptor-tyrosine kinase inhibitor-progressed nonsmall cell lung carcinoma patients: an expert opinion. Indian J Cancer. 2017;54(5):31–6.CrossRef
93.
Zurück zum Zitat Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26–75ra26. Sequist LV, Waltman BA, Dias-Santagata D, et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 2011;3(75):75ra26–75ra26.
94.
Zurück zum Zitat Ji W, Choi C-M, Rho JK, et al. Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer. BMC Cancer. 2013;13(1):606.CrossRefPubMedPubMedCentral Ji W, Choi C-M, Rho JK, et al. Mechanisms of acquired resistance to EGFR-tyrosine kinase inhibitor in Korean patients with lung cancer. BMC Cancer. 2013;13(1):606.CrossRefPubMedPubMedCentral
95.
Zurück zum Zitat Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–7.CrossRefPubMedPubMedCentral Yu HA, Arcila ME, Rekhtman N, et al. Analysis of tumor specimens at the time of acquired resistance to EGFR-TKI therapy in 155 patients with EGFR-mutant lung cancers. Clin Cancer Res. 2013;19(8):2240–7.CrossRefPubMedPubMedCentral
96.
Zurück zum Zitat Nguyen K-SH, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 2009;10(4):281–289. Nguyen K-SH, Kobayashi S, Costa DB. Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer. 2009;10(4):281–289.
97.
Zurück zum Zitat Ercan D, Choi HG, Yun C-H, et al. EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors. Clin Cancer Res. 2015;21(17):3913–23.CrossRefPubMedPubMedCentral Ercan D, Choi HG, Yun C-H, et al. EGFR mutations and resistance to irreversible pyrimidine-based EGFR inhibitors. Clin Cancer Res. 2015;21(17):3913–23.CrossRefPubMedPubMedCentral
98.
Zurück zum Zitat Stewart EL, Tan SZ, Liu G, Tsao M-S. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review. Transl Lung Cancer Res. 2015;4(1):67.PubMedPubMedCentral Stewart EL, Tan SZ, Liu G, Tsao M-S. Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations—a review. Transl Lung Cancer Res. 2015;4(1):67.PubMedPubMedCentral
99.
Zurück zum Zitat Li H, Hu H, Wang R, et al. Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. OncoTargets Therapy. 2014;7:513.CrossRefPubMedPubMedCentral Li H, Hu H, Wang R, et al. Primary concomitant EGFR T790M mutation predicted worse prognosis in non-small cell lung cancer patients. OncoTargets Therapy. 2014;7:513.CrossRefPubMedPubMedCentral
100.
Zurück zum Zitat Su K-Y, Chen H-Y, Li K-C, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 2012;30(4):433–40.CrossRefPubMed Su K-Y, Chen H-Y, Li K-C, et al. Pretreatment epidermal growth factor receptor (EGFR) T790M mutation predicts shorter EGFR tyrosine kinase inhibitor response duration in patients with non-small-cell lung cancer. J Clin Oncol. 2012;30(4):433–40.CrossRefPubMed
101.
Zurück zum Zitat Chougule A, Basak S. Epidermal growth factor receptor T790M testing in progressed lung cancer: a review of sensitive methods for analysis of tissue and liquid biopsy samples. Indian J Cancer. 2017;54(5):45–54.CrossRef Chougule A, Basak S. Epidermal growth factor receptor T790M testing in progressed lung cancer: a review of sensitive methods for analysis of tissue and liquid biopsy samples. Indian J Cancer. 2017;54(5):45–54.CrossRef
102.
Zurück zum Zitat Zanwar S, Noronha V, Joshi A, et al. Repeat biopsy in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer: feasibility, limitations, and clinical utility in Indian patients. Indian J Cancer. 2017;54(1):280–4.CrossRefPubMed Zanwar S, Noronha V, Joshi A, et al. Repeat biopsy in epidermal growth factor receptor mutation-positive nonsmall cell lung cancer: feasibility, limitations, and clinical utility in Indian patients. Indian J Cancer. 2017;54(1):280–4.CrossRefPubMed
103.
Zurück zum Zitat Ballard P, Yates JW, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22(20):5130–40.CrossRefPubMed Ballard P, Yates JW, Yang Z, et al. Preclinical comparison of osimertinib with other EGFR-TKIs in EGFR-mutant NSCLC brain metastases models, and early evidence of clinical brain metastases activity. Clin Cancer Res. 2016;22(20):5130–40.CrossRefPubMed
104.
Zurück zum Zitat Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017;376(7):629–40.CrossRefPubMed Mok TS, Wu YL, Ahn MJ, et al. Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer. N Engl J Med. 2017;376(7):629–40.CrossRefPubMed
105.
Zurück zum Zitat Ricciuti B, Chiari R, Chiarini P, et al. Osimertinib (AZD9291) and CNS response in two radiotherapy-naive patients with EGFR-mutant and T790M-positive advanced non-small cell lung cancer. Clin Drug Investig. 2016;36(8):683–6.CrossRefPubMed Ricciuti B, Chiari R, Chiarini P, et al. Osimertinib (AZD9291) and CNS response in two radiotherapy-naive patients with EGFR-mutant and T790M-positive advanced non-small cell lung cancer. Clin Drug Investig. 2016;36(8):683–6.CrossRefPubMed
106.
Zurück zum Zitat John T, Bowden JJ, Clarke S, et al. Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer. Asia-Pac J Clin Oncol. 2017;13(4):296–303.CrossRefPubMed John T, Bowden JJ, Clarke S, et al. Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer. Asia-Pac J Clin Oncol. 2017;13(4):296–303.CrossRefPubMed
107.
Zurück zum Zitat Zarogoulidis P, Gaga M, Huang H, Darwiche K, Rapti A, Hohenforst-Schmidt W. Tissue is the issue and tissue competition. Re-biopsy for mutation T790: where and why? Clin Transl Med. 2017;6:6. Zarogoulidis P, Gaga M, Huang H, Darwiche K, Rapti A, Hohenforst-Schmidt W. Tissue is the issue and tissue competition. Re-biopsy for mutation T790: where and why? Clin Transl Med. 2017;6:6.
108.
Zurück zum Zitat Campo M, Gerber D, Gainor JF, et al. Acquired resistance to first-line afatinib and the challenges of prearranged progression biopsies. J Thoracic Oncol. 2016;11(11):2022–6.CrossRef Campo M, Gerber D, Gainor JF, et al. Acquired resistance to first-line afatinib and the challenges of prearranged progression biopsies. J Thoracic Oncol. 2016;11(11):2022–6.CrossRef
109.
Zurück zum Zitat Wu YL, Wang CL, Sun Y, et al. A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. ESMO Open. 2017;2(Suppl 1):e000174.CrossRefPubMedPubMedCentral Wu YL, Wang CL, Sun Y, et al. A consensus on liquid biopsy from the 2016 Chinese Lung Cancer Summit expert panel. ESMO Open. 2017;2(Suppl 1):e000174.CrossRefPubMedPubMedCentral
110.
Zurück zum Zitat Wu YL, Sequist LV, Hu CP, et al. EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. Br J Cancer. 2017;116(2):175–85.CrossRefPubMed Wu YL, Sequist LV, Hu CP, et al. EGFR mutation detection in circulating cell-free DNA of lung adenocarcinoma patients: analysis of LUX-Lung 3 and 6. Br J Cancer. 2017;116(2):175–85.CrossRefPubMed
111.
Zurück zum Zitat Stockley T, Souza CA, Cheema PK, et al. Evidence-based best practices for EGFR T790M testing in lung cancer in Canada. Curr Oncol. 2018;25(2):163–9.CrossRefPubMedPubMedCentral Stockley T, Souza CA, Cheema PK, et al. Evidence-based best practices for EGFR T790M testing in lung cancer in Canada. Curr Oncol. 2018;25(2):163–9.CrossRefPubMedPubMedCentral
112.
Zurück zum Zitat Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61(1):112–23.CrossRefPubMed Heitzer E, Ulz P, Geigl JB. Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem. 2015;61(1):112–23.CrossRefPubMed
113.
Zurück zum Zitat De Mattos-Arruda L, Mayor R, Ng CK, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839.CrossRefPubMedPubMedCentral De Mattos-Arruda L, Mayor R, Ng CK, et al. Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun. 2015;6:8839.CrossRefPubMedPubMedCentral
114.
Zurück zum Zitat Warton K, Yuwono NL, Cowley MJ, McCabe MJ, So A, Ford CE. Evaluation of streck BCT and PAXgene stabilised blood collection tubes for cell-free circulating DNA studies in plasma. Mol Diagn Ther. 2017;21(5):563–70.CrossRefPubMed Warton K, Yuwono NL, Cowley MJ, McCabe MJ, So A, Ford CE. Evaluation of streck BCT and PAXgene stabilised blood collection tubes for cell-free circulating DNA studies in plasma. Mol Diagn Ther. 2017;21(5):563–70.CrossRefPubMed
115.
Zurück zum Zitat Plieskatt JL, Feng Y, Rinaldi G, Mulvenna JP, Bethony JM, Brindley PJ. Circumventing qPCR inhibition to amplify miRNAs in plasma. Biomark Res. 2014;2:13.CrossRefPubMedPubMedCentral Plieskatt JL, Feng Y, Rinaldi G, Mulvenna JP, Bethony JM, Brindley PJ. Circumventing qPCR inhibition to amplify miRNAs in plasma. Biomark Res. 2014;2:13.CrossRefPubMedPubMedCentral
116.
Zurück zum Zitat Veldore VH, Choughule A, Routhu T, et al. Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer. Lung Cancer (Auckland, N.Z.). 2018;9:1–11. Veldore VH, Choughule A, Routhu T, et al. Validation of liquid biopsy: plasma cell-free DNA testing in clinical management of advanced non-small cell lung cancer. Lung Cancer (Auckland, N.Z.). 2018;9:1–11.
117.
Zurück zum Zitat Chatterjee K, Ray A, Chattopadhyay B. Incidence and characteristics of Epidermal Growth Factor Receptor (EGFR) mutation in non-small-cell lung cancer (Adenocarcinoma histology): a report of 106 patients from Kolkata. Indian J Cancer. 2017;54(1):305–7.CrossRefPubMed Chatterjee K, Ray A, Chattopadhyay B. Incidence and characteristics of Epidermal Growth Factor Receptor (EGFR) mutation in non-small-cell lung cancer (Adenocarcinoma histology): a report of 106 patients from Kolkata. Indian J Cancer. 2017;54(1):305–7.CrossRefPubMed
118.
Zurück zum Zitat Sheikine Y, Rangachari D, McDonald DC, et al. EGFR testing in advanced non-small-cell lung cancer. A mini-review. Clin Lung Cancer. 2016;17(6):483–92.CrossRefPubMed Sheikine Y, Rangachari D, McDonald DC, et al. EGFR testing in advanced non-small-cell lung cancer. A mini-review. Clin Lung Cancer. 2016;17(6):483–92.CrossRefPubMed
119.
Zurück zum Zitat Normanno N, Denis MG, Thress KS, Ratcliffe M, Reck M. Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer. Oncotarget. 2017;8(7):12501–16.CrossRefPubMed Normanno N, Denis MG, Thress KS, Ratcliffe M, Reck M. Guide to detecting epidermal growth factor receptor (EGFR) mutations in ctDNA of patients with advanced non-small-cell lung cancer. Oncotarget. 2017;8(7):12501–16.CrossRefPubMed
120.
Zurück zum Zitat Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay. Clin Cancer Res. 2011;17(5):1169–80.CrossRefPubMedPubMedCentral Arcila ME, Oxnard GR, Nafa K, et al. Rebiopsy of Lung Cancer Patients with Acquired Resistance to EGFR Inhibitors and Enhanced Detection of the T790M Mutation Using a Locked Nucleic Acid-Based Assay. Clin Cancer Res. 2011;17(5):1169–80.CrossRefPubMedPubMedCentral
121.
Zurück zum Zitat Zhao J, Feng H, Zhao J, et al. A sensitive and practical method to detect the T790M mutation in the epidermal growth factor receptor. Oncol Lett. 2016;11(4):2573–9.CrossRefPubMedPubMedCentral Zhao J, Feng H, Zhao J, et al. A sensitive and practical method to detect the T790M mutation in the epidermal growth factor receptor. Oncol Lett. 2016;11(4):2573–9.CrossRefPubMedPubMedCentral
122.
Zurück zum Zitat Shao D, Lin Y, Liu J, et al. A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma. Sci Rep. 2016;6:22338.CrossRefPubMedPubMedCentral Shao D, Lin Y, Liu J, et al. A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma. Sci Rep. 2016;6:22338.CrossRefPubMedPubMedCentral
123.
Zurück zum Zitat Malapelle U, Sirera R, Jantus-Lewintre E, et al. Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer. Expert Rev Mol Diagn. 2017;17(3):209–15.CrossRefPubMed Malapelle U, Sirera R, Jantus-Lewintre E, et al. Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer. Expert Rev Mol Diagn. 2017;17(3):209–15.CrossRefPubMed
Metadaten
Titel
Biomarkers in Non-Small Cell Lung Cancers: Indian Consensus Guidelines for Molecular Testing
verfasst von
Kumar Prabhash
Suresh H. Advani
Ullas Batra
Bivas Biswas
Anuradha Chougule
Mithua Ghosh
Vamshi Krishna Muddu
T. P. Sahoo
Ashok K. Vaid
Publikationsdatum
12.03.2019
Verlag
Springer Healthcare
Erschienen in
Advances in Therapy / Ausgabe 4/2019
Print ISSN: 0741-238X
Elektronische ISSN: 1865-8652
DOI
https://doi.org/10.1007/s12325-019-00903-y

Weitere Artikel der Ausgabe 4/2019

Advances in Therapy 4/2019 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.